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Scope and Method of Study: Neuropathic pain is a common complication of peripheral 
nerve injuries. In pain studies, it has been revealed that glutamate neurotransmission has 
a critical role in the noxious stimulus sensation. The glutamate cycle have several well 
established markers: vesicular glutamate transporters 1 & 2 and glutaminase. However, 
systemic studies for vesicular glutamate transporters 1 & 2 and glutaminase changes after 
peripheral nerve injuries have not been done. Thus, in this thesis project we studied the 
changes in vesicular glutamate transporters 1 & 2 and glutaminase systemically through 
immunohistochemistry at six different time points that represent the acute (day 1 & 2), 
subacute (day 7 & 14), and chronic (day 28 & 70) phases in peripheral nerve 
regeneration. Our peripheral nerve injury models, nerve crush and nerve transection, 
imitate two types of peripheral nerve injury in human, axonotmesis and neurotemsis, 
respectively.  
Findings and Conclusions: The study of subacute phase of peripheral nerve regeneration 
in sciatic nerve crush model showed an elevation of dorsal root ganglia neurons VGLUT 
2 immunoreactivity only at day 7 post injury. On the other hand, the study of VGLUT 1 
& 2 and glutaminase dorsal root ganglia neurons immunoreactivity in the acute, subacute, 
and chronic phase of regeneration showed a pattern of elevation and reduction in the 
glutamate metabolism cycle. A minor increase in the three markers immunoreactivity at 
day 1 followed by marked decrease at day 2. In subacute phase VGLUT 1 & 2 and 
glutaminase immunoreactivity levels return to control levels at day 7, however, at day 14 
they showed an increase above control levels. Finally at the chronic phase of 
regeneration, the three markers show a decrease in immunoreactivity levels initially (day 
28) then return to control levels at day 70 post injury. In conclusion, our 
immunohistochemistry studies for vesicular glutamate transporters 1 & 2 and glutaminase 
gave insight into part of the story of neuronal response to injury. By understanding the 
molecular and physiological changes after peripheral nerve injuries, potential 
pharmacological or other treatments could be designed to improve the functional 
outcome of those injuries.   
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Peripheral nerve injury in the lower extremity is very common and serious nerve 
injuries affect 2-3 % of trauma patients [1]. Usually the injury affects either the sciatic or 
peroneal nerve [2]. The sciatic nerve originates from the sacral plexus (L4, L5, S1, S2, 
and S3) and it contains sensory, motor and autonomic axons. It bifurcates above the knee 
to the tibial and common peroneal nerve. These nerves innervate some of the muscles 
controlling knee and ankle joint flexion and extension as well as carrying the sensory 
information from lateral side of the calf and the fifth toe [3]. The causes of sciatic nerve 
injury vary from femoral fractures, laceration, contusions, and compression to gunshot 
wounds and total hip replacement surgery.  
Peripheral nerve injuries in human are classified into three types depending on the 
severity of the injury [4]. The injuries are nerve compression with or without 
demyelination (neurapraxia), axon transection with both perineurium and epineurium 
remaining intact (axonotmesis), and nerve transection with disruption of the continuity of 
epineurium (neurotemsis). The recovery outcome of each type varies drastically. Usually, 
neurapraxia and axonotmesis have very good recovery outcomes with complete or near 
complete function. In neurotemsis, however, the recovery outcome is poor in most cases. 
Functional level of recovery is probable only in a few cases after nerve repair and other  
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correction surgeries [2]. The injured nerve usually takes a long time to regenerate. 
Typically, axon regeneration progresses at the speed of 1 mm/day in humans and 3 
mm/day in animals [5]. Because of this slow regrowth, several complications may 
include muscle contraction and neuropathic pain [1].  
 Although peripheral nerves are capable of regenerating their axons after injury, 
patients typically have a poor functional recovery outcome. Patients with severe 
peripheral nerve injury usually have devastating permanent impairments. Thus, the need 
for better and faster treatment of nerve injuries inspires researchers to investigate 
peripheral nerve injuries and their complications. Several models of peripheral nerve 
injury have been developed that imitate the injuries to peripheral nerves seen in human. 
Injury of the sciatic nerve in rat is an optimal model to study the complexity of nerve 
injury and its recovery process [3]. Most of our understanding of regeneration of the 
peripheral nerve comes from models using injury to the sciatic nerve [1]. The nerve crush 
model imitates axonotmesis while the nerve transection model imitates neurotemsis. If 
nerve repair follows in the nerve transection model, it can lead to the development of 
neuropathic pain that manifests as an abnormal response to thermal and tactile stimuli. 
This is very similar to human nerve injury where neuropathic pain is a common 
complication. On the other hand, autotomy (self-mutilation), skin laceration, and limb 
contraction are common complication of the nerve transection model in rat [1].  
 The study of peripheral nerve injury in rat models has laid the groundwork of the 
molecular and physiological events that occur during this process. Nerve injury where the 
axonal continuity is disrupted triggers cell body responses that include chromatolysis, 
e.g., morphological changes including swelling, movement of the nucleus and nucleolus 
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to an eccentric position, and dissolution of the Nissl bodies. These morphological 
changes along with altered gene expression are required for axon regeneration. Gene 
alterations include the upregulation of growth associated genes such as actin, tubulin, and 
growth associated protein 43 (Gap43) and the downregulation of the neurofilament gene. 
At the injury site, the transected nerve (distal nerve stump) undergoes Wallerian 
degeneration, a process where severed axons exhibit an anterograde and retrograde 
degeneration [5]. After surgical repair of the transected nerve, however, outgrowing 
axons cross the surgical repair site in a staggered fashion over a prolonged period of 4 
weeks in a rat [6].  
 In this study two models of peripheral nerve injury were used, sciatic nerve crush 
and sciatic nerve transection, which imitate the two types of peripheral nerve injury in 
humans, axonotmesis and neurotemsis, respectively. The primary goal of treatment in 
patients with sciatic nerve injury is the restoration of protective sensation in the sole [2]. 
In addition, a common consequence of nerve injury is neuropathic pain and providing 
pain relief is another goal following nerve injury. Thus, we investigated the molecular 
changes in the metabolism cycle of glutamate in cells of the dorsal root ganglia (DRG). 
Glutamate is an essential neurotransmitter regulating both normal and painful stimuli and 
it is probably used in the regenerating peripheral axon.     
 Glutamate from cells of the DRG is released as a neurotransmitter in both central 
and peripheral nerve terminals. The release of glutamate after specific types of 
stimulation in the periphery indicates that DRG neurons are participating in the peripheral 
metabolic cycle of glutamine [7]. In the glutamine cycle, glutamine is converted to 
glutamate to be used as neurotransmitter [8] through a multistep cycle (Figure 1.1). After 
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release of glutamate from DRG neurons nearby glial cells quickly remove excess 
glutamate from the intracellular space via a glutamate–aspartate transporter (GLAST) and 
glutamate transporter 1 (GLT-1). In peripheral nerve, glutamate in Satellite or Schwann 
cells is converted to glutamine via glutamine synthetase (GS). Alternatively, glutamate is 
transported to the mitochondria to be a part of the TCA cycle. Converted glutamine is 
transported back to the neurons via sodium-coupled neutral amino acid transporters 
(SNAT) and converted back to glutamate by Glutaminase within the mitochondria of 
DRG neurons. Neurons transport glutamate from the mitochondria to the cytoplasm to be 
packaged into vesicles via vesicular glutamate transporter 1 or 2 [9].  
Figure 1.1: Glutamine cycle in the peripheral nervous system.  
 In this series of studies, I hypothesized that glutamate metabolism in dorsal root 
ganglia neurons would change following peripheral nerve injury in response to a transient 
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inflammatory state and as an accommodation for the needs of the regenerating nerve. I 
utilized two peripheral nerve injury models: sciatic nerve crush and sciatic nerve 
transection to study the changes in vesicular glutamate transporter 1 & 2 and 
glutaminase; known markers for glutamate metabolism cycle. In the sciatic nerve 
transection model, I sutured the nerve for alignment to prevent the regenerating nerve 
forming a neuroma. I utilized immunohistochemistry to evaluate the changes in vesicular 
glutamate transporter 1 & 2 and glutaminase at six time points: 1, 2, 7, 14, 28, 70 days. 
Each pair of two time points, e.g., 1, 2 or 7, 14 or 28, 70; represent acute, subacute and 






VESICULAR GLUTAMATE TRANSPORTER 2 EXPRESSION IS ALTERED IN 
RAT DORSAL ROOT GANGLION NEURONS DURING THE REGENERATIVE 
PHASE FOLLOWING SCIATIC NERVE CRUSH 
1. Introduction 
Glutamate is the most abundant excitatory neurotransmitter in the adult central 
nervous system (CNS) [10]. It has critical role in CNS function and many defects in 
glutamate signaling have been linked to several diseases [11]. Furthermore, several 
studies show a direct link between peripheral injuries or inflammation and changes in the 
activity of glutamate metabolism [9, 12]. The discovery of vesicular glutamate 
transporters 1, 2, and 3 had an enormous role in the advancement of glutamate related 
studies. Hence, these vesicular glutamate transporters enabled researchers to accurately 
identify glutamatergic neurons [11].  
Dorsal root ganglion (DRG) neurons are glutamatergic using glutamate as the 
primary neurotransmitter at central terminals.  Many DRG neurons also release glutamate 
from their peripheral terminals in response to noxious or injurious stimuli [9]. Previous 
studies indicate that glutamate metabolism is altered in DRG neurons after axonal injury. 
Following sciatic nerve transection in rats, glutamate levels double in the nerve at 15 
days post-injury [13]. After dorsal root crush in cats, glutamate levels in the DRG 
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decrease from 2-4 days, but regain normal levels from 10-25 days [14]. Glutamate levels 
are diminished 4-25 days in dorsal roots following dorsal root crush [14]. Sciatic nerve 
transection in mice at 7 days decreases the overall number of DRG neurons for vesicular 
glutamate transporters 1 & 2 (VGLUT 1, 2) [12]. Despite an overall decrease in neuronal 
cells, VGLUT 2 increases in a subpopulation of small diameter neurons after 7 days of 
sciatic nerve transection [12]. However, the effect of peripheral nerve injury or 
regeneration on DRG glutamate metabolism has not been studied systematically. 
In the present study, we evaluated vesicular glutamate transporter 2, a marker of 
glutamatergic function, in DRG cell bodies during the regenerative phase following 
sciatic nerve crush in the rat. Glutamate is produced from glutamine by glutaminase, the 
primary synthetic enzyme in the neuronal/glial glutamine cycle [9]. After synthesis, 
glutamate is packaged into synaptic vesicles by VGLUT2 [9]. In addition, to verify if our 
crush model indeed produces a regenerative nerve injury, we simultaneously evaluated 
growth associated protein (Gap43). Gap 43 is a known marker for axonal regeneration. I 
evaluated VGLUT2 and Gap 43 in DRG with immunohistochemistry at 7 and 14 days 
after crush of the sciatic nerve 
2. Materials and Methods 
2.1. Animals: 
Adult Sprague Dawley rats (n=9; 250-350 g) were housed in a 12-hr-light: 12-hr-
dark cycle and given free access to food and water. Procedures were approved by the 
Oklahoma State University Center for Health Sciences Institutional Animal Care and Use 
Committee. All appropriate efforts were made to minimize the number of animals used in 
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this study. Rats were randomly assigned to specific experiments, irrespective of their 
gender. Gender differences were not investigated in this study. 
2.2. Surgery:  
All surgeries were performed on animals anesthetized by 2%-3% isoflurane 
inhalation. Under deep anesthesia, the rat right sciatic nerve was exposed at mid-thigh 
level. With fine hemostats (2.5mm), the nerves were strongly compressed for 30 s twice. 
Muscles and skin were sutured in layers. The animals were allowed to recover from the 
anesthesia in a warmed cage and then were housed individually until the day of 
perfusion.  Sham-operated rats were used as control. 
2.3. Tissue Preparation: 
Rats were anesthetized with tribromoethanol [Avertin; 2.5% (w/v)] and xylazine 
and perfused through the ascending aorta with 75 ml of calcium-free Tyrode’s solution 
(pH 7.3), followed by 300 ml of fixative 0.2% paraformaldehyde (w/v), 0.8% (w/v) picric 
acid in 0.1M phosphate buffer, pH 7.3 [15,16]. Right L4 DRG was removed and placed 
for 4hrs in the same fixative used for perfusion at 4C. DRGs were transferred to 20% 
sucrose in 0.1M phosphate buffer, pH 7.3 for 24–48 hrs at 4C.  
2.4. Immunofluorescence:  
Immunohistochemical localization of VGLUT 2 and Gap43 were performed for 
two different experimental time points: 7 and 14 days post right sciatic nerve crush 
(SNC), and sham rats.  The tissue was frozen, sectioned at 12 μm with a Leica CM 1850 
Leica (Microsystem Inc. Bannockbum, IL). Sections were thaw mounted to gelatin-
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coated SuperFrost slides (Fisher Scientific; Pittsburg, PA) and dried for 1 hr at 37C. 
Every fifth section was used to reduce the possibility of evaluating a neuron twice. 
Sections were washed three times for 10 min in phosphate buffered saline (PBS) and 
incubated in 0.5% bovine serum albumin (BSA), and 0.5% polyvinylpyrolidone (PVP) in 
PBS with 0.3% Triton X-100 (PBS-T) and primary antiserum for 4 days at 4C. For 
VGLUT 2 detection, mouse antiserum against VGLUT 2 was used at 1:4000 dilution and 
for Gap43 detection, rabbit antiserum (AbDSerotec) was used at 1:4000 dilution. The 
tissue was rinsed three times in PBS and incubated in secondary antisera:  Biotinylated 
Goat anti-Mouse IgG 1:1500 and FITC-Avidin 1:500 in PBS-T  (VGLUT2 detection) and 
in Cy3 Donkey anti-Rabbit IgG in PBS-T 1:1500 (Gap43 detection)  for 1 hr at room 
temperature. Sections were rinsed two times in PBS following secondary antibody 
incubation, and then incubated in DAPI for nucleus staining for 15 min. All sections were 
rinsed three more times in PBS and coverslipped with ProLong Gold mounting medium 
(Molecular Probes). 
2.5. Image analysis: 
Images were acquired using a 20Χ objective on an Olympus BX51 
epifluorescence microscope (Olympus; Center Valley, PA) equipped with a SPOT RT740 
quantitative camera (Diagnostic Instruments; SterlingHeights, MI). Three random fields 
of view were imaged for each DRG section. Images were saved as uncompressed TIFF 
files. The exposure time for all images was the same for all tissue sections from all 
animals. The exposure time was determined empirically so that weakly stained neurons 
could be distinguished for tracing, but that intensely stained neurons were not 
oversaturated [16, 17]. This approach allowed images to be evaluated along the linear 
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aspect of immunofluorescence intensity [17].   Captured images were 1600 × 1200 pixels 
with 2.69 pixels per micrometer. All neuron profiles with clearly visible nuclei that were 
not touching the edge of the image were traced with a Cintiq 21UX interactive pen 
display (Wacom; Kita Saitama-Gun, Saitama, Japan), using the freehand selection tool in 
Image J software (NIH). Nuclei were excluded from the regions of interest, making each 
region of interest correspond to the cytoplasmic profile of a single DRG neuron [16,17] 
Images were acquired at a bit depth of 8, so pixel intensities ranged from 0 (darkest) to 
255 (lightest) on a grayscale. The mean gray value and area in µm
2
 for each cytoplasmic 
profile were measured and copied to an Excel spreadsheet. The values for area (µm
2
) 
were binned into small (<400 µm
2
), medium (400–799.99 µm
2
), and large (≥800 µm
2
) 
sized categories to indicate three broadly defined neuronal subpopulations that 
corresponded to C, Aδ, and Aα/β fibers, respectively [18, 19].  
2.6. Statistic:  
Data from the analyses are reported as mean value with standard error of the 
mean. A one-way ANOVA test, followed by Tukey test was used to determine 
differences between nerve injury and control groups (Prism version 5.01, GraphPad 
Software Inc., San Diego, CA). In all analysis, P values less than 0.05 were considered 
significant.  
3. Results 
3.1. VGLUT2 IR: 
At 7 days, VGLUT2 immunoreactivity (IR) in L4 DRG neurons post SNC 
qualitatively was increased compared to DRG neurons from sham operated rats (Figure 
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2.1 a, d, & g). Therefore, the VGLUT2 IR intensities of the total immunoreactive neurons 
and of the three different sizes of DRG cell bodies were analyzed (Figure 2.2). The 
overall VGLUT 2 IR intensity of L4 DRG cell bodies (Figure 2.2) from the SNC rats 
(155.3 ± 1/µm
2
) was greater (P< 0.05) than sham operated rats (113.3 ± 20/µm
2
). This 
increase in VGLUT2 intensity was diminished by day 14 post injury (126.2 ± 2.3/µm
2
). 
For both 7 and 14 days post SNC there was no significant difference in any of the size 
subgroups in VGLUT2 IR in comparison with sham operated DRG neurons (Figure 2.2).   
 
Figure 2.1: Vesicular glutamate transporter 2 (green), Gap43 (red), and merge of both 
immunoreactivities (IR) in rat L4 dorsal root ganglia (DRG) following 7 (subfigures d,e, 
f) and 14 (subfigures g,h, i) days post right sciatic nerve crush (SNC). DRG sections were 
processed simultaneously with a mouse VGLUT 2 and rabbit Gap43 antiserum and 
photographed under identical conditions. In sham operated sections, VGLUT 2 IR (a) 
was light to moderate in all neuronal cell sizes. Gap43 IR (b) was light to moderate in 
small and medium neuronal cell sizes. Elevated VGLUT 2 IR (d) in all neuronal cell sizes 
occurred in the DRG 7 days post SNC. Elevated Gap43 IR (e & h) in small and medium 





















































































































Figure 2.2: Image analysis of vesicular glutamate transporter 2 (VGLUT 2) 
immunoreactivity (IR) in L4 DRG neurons after 7 and 14 days of sciatic nerve crush 
(SNC). Data are presented as intensity divided by the area of the cell (mean grey 
intensity, MGI). DRG neurons were categorized into three area size groups: small (<400 
µm2), medium (400–799.99 µm2), and large (≥800 µm2). Overall VGLUT 2 IR 
increased at 7 days compared to sham.  Although diminished at day 14, VGLUT 2 was 
still elevated compared to sham.  This overall increase was similar to what was observed 
in small, medium, and large subgroups.* 7 days compared to sham, ** 7 days compared 
to 14 days. (*,** P < 0.05). One-way ANOVA followed by Tukey test were used.    
3.2. Gap43 IR: 
Gap43 IR was elevated mainly in L4 small and medium sized DRG neurons post 
SNC at day 7 and 14 (Figure 2.1b, e, & h) [6, 7]. At day 7, the overall Gap43 IR intensity 
of L4 DRG cell bodies (Figure 2.3-A) from the SNC rats (63.64 3 ± 1/µm2) was greater 
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(P< 0.05) than sham operated rats (39.66 ± 1.4/µm2). At day 14, the overall Gap43 IR 
intensity of L4 DRG cell bodies from the SNC rats (54.67 ± 2/µm2) was greater (p < 
0.05) than sham operated rats (39.66 ± 1.4/µm2) but less than 7 days post SNC (63.64 3 ± 
1/µm2). This pattern of intensity increasing at day 7 post SNC then decreasing at day 14 
post SNC was consistent in all DRG neuronal subgroups. 
TOTAL GAP43

































































































Figure 2.3: Image analysis of Gap43 immunoreactivity (IR) in L4 DRG neurons after 7 
and 14 days of sciatic nerve crush (SNC). Data are presented as intensity divided by the 
area of the cell. DRG neurons were categorized into three area size groups: small (<400 
µm2), medium (400–799.99 µm2), and large (≥800 µm2). Overall GAP 43 
immunoreactivity increased at 7 and 14 days compared to sham. This overall increase 
was similar to what was observed in small, medium, and large subgroups. (* P < 0.05). 
One-way ANOVA followed by Tukey test were used. 
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3.3. Co-localization of VGLUT2 and Gap43: 
VGLUT2 and Gap43 IR showed co-localization behavior primarily in L4 small 
and medium sized DRG neurons (Figure 2.1c, f, & i). Most of small to medium Gap43 IR 
neurons were double stained with VGLUT2. However, large DRG neurons showed no or 
little double staining for both VGLUT2 and Gap43. 
4. Discussion 
DRG neurons primarily use glutamate as their excitatory neurotransmitter [9]. In 
pathological conditions, DRG neurons constantly modify their neurotransmitter 
concentration and production [15]. One valid marker of glutamate cycle metabolism is 
vesicular glutamate transporter 2 (VGLUT2) [11]. For nerve injury experiments, the SNC 
model is an accepted model for axonotmesis to study nerve regeneration [20]. In this 
study, I evaluated the changes in immunoreactivity for VGLUT2 and Gap 43, a known 
marker for regeneration, in DRG neuronal cell bodies 7 and 14 days post sciatic nerve 
crush. 
Our results showed Gap43 to be elevated at day 7 and 14 post SNC (Figure 2.3). 
This is consistent with previous studies in the regeneration field demonstrating increases 
in Gap43 IR at day 4. Gap43 IR continues to be elevated 9 weeks post injury with a peak 
at day 21 in DRG neuronal cell bodies [21, 22].Thus, I can say my SNC model indeed 
produces a nerve injury that results in a regenerative phase.  
VGLUT 2 is elevated in DRG neuronal cell bodies during the regenerative phase 
following SNC in the rat (Figure 2.2).  Since VGLUT2 is important for vesicular release 
of glutamate, the elevation in VGLUT2 immunoreactivity may indicate increased 
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glutamatergic neurotransmission in the spinal cord to provide information to the CNS 
concerning the regenerative process.  Alternatively, vesicular release of glutamate may be 
occurring at the regenerating peripheral process to regulate the local environment of the 
outgrowing axons. 
Further studies are needed to establish VGLUT2 activity changes in DRG 
following different model of regeneration. In addition, to determine if changing VGLUT2 
levels is an acute response or a prolonged activity change, longer time periods post injury 






VESICULAR GLUTAMATE TRANSPORTER 2 EXPRESSION IS ALTERED IN 
RAT DORSAL ROOT GANGLION NEURONS DURING THE REGENERATIVE 
PHASE FOLLOWING SCIATIC NERVE TRANSECTION 
1. Introduction 
Pain is a defense mechanism produced by the central nervous system to alert the 
body of dangerous conditions either internally or externally. One of the many examples 
of a painful situation is peripheral nerve injury [23]. This painful stimulus is detected by 
dorsal root ganglia (DRG) neurons and transmitted to the spinal cord neurons via 
glutamatergic neurotransmission utilizing vesicular glutamate transporters in presynaptic 
nerve terminals [16]. Glutamate is the most abundant excitatory neurotransmitter in the 
adult central nervous system (CNS) [10]. Glutamate is transported into vesicles by the 
VGLUT’s 1, 2, or 3 [24]. Discovery of these vesicular glutamate transporters provided a 
mechanism for the identification of glutamate signaling neurons [11]. In addition, by 
controlling the activity of VGLUT proteins, neurons can modify the efficiency of 
glutamatergic neurotransmission [24]. Previous studies indicate that glutamate 
metabolism is altered in DRG neurons after axonal injury. Following sciatic nerve 
transection in rats, glutamate levels double in the nerve at 15 days post-injury [13].
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Sciatic nerve transection in mice at 7 days decreases the overall number of DRG neurons 
immunoreactive for vesicular glutamate transporters 1 & 2 [12]. Despite an overall 
decrease, VGLUT 2 increases in a subpopulation of small diameter neurons after 7 days 
of sciatic nerve transection in mice [12]. However, the effect of peripheral nerve injury or 
regeneration on DRG glutamate metabolism has not been studied systematically. 
In the present study, I evaluated vesicular glutamate transporter 2 a marker of 
glutamatergic function in DRG neuronal cell bodies during the inflammatory and 
regenerative phases following sciatic nerve transection and resection in the rat. 
Transecting the nerve without any surgical repair results in that axons regenerate without 
any directionality and that lead to the formation of neuroma. By suturing the proximal 
and distal ends of the transected nerve, I allow the nerve to regenerate in the correct 
direction toward the distal end rather than forming a neuroma.  VGLUT2 was evaluated 
in DRG neuronal cell bodies and peripheral axons with immunohistochemistry at day 1, 
2, 7, 14, 28, and 70 after transection and resection of the sciatic nerve (SNT). 
2. Materials and Methods 
2.1. Animals: 
Adult Sprague Dawley rats (n=27; 250-350 g) were housed in a 12-hr-light: 12-
hr-dark cycle and given free access to food and water. Procedures were approved by the 
Oklahoma State University Center for Health Sciences Institutional Animal Care and Use 
Committee. All appropriate efforts were made to minimize the number of animals used in 
this study. Rats were randomly assigned to specific experiments, irrespective of their 
gender. Gender differences were not investigated in this study. 
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2.2. Surgery:  
All surgeries were performed on animals anesthetized by 2%-3% isoflurane 
inhalation. Under deep anesthesia, the rat right sciatic nerve was exposed at mid-thigh 
level and cut with a sharp blade. The nerve was reapposed and sutured using ETHILON 
8-0 black monofilament Nylon for alignment. Muscles and skin were sutured in layers. 
The animals were allowed to recover from the anesthesia in a warmed cage and then were 
housed individually until the day of perfusion.  Naïve rats were used as control.  
2.3. Tissue Preparation: 
Rats were anesthetized with tribromoethanol [Avertin;2.5% (w/v)] and xylazine 
and perfused through the ascending aorta with 75 ml of calcium-free Tyrode’s solution 
(pH 7.3), followed by 300 ml of fixative 0.2% paraformaldehyde (w/v), 0.8% (w/v) picric 
acid in 0.1M phosphate buffer, pH 7.3 [16]. Right L4 DRG and sciatic nerve were 
removed and placed for 4 hrs. in the same fixative used for perfusion at 4C. DRGs were 
transferred to 20% sucrose in 0.1M phosphate buffer, pH 7.3 for 24–48 hrs. at 4C.  
2.4. Immunofluorescence:  
Immunohistochemical localization of VGLUT 2 was performed for six different 
experimental time points: 1, 2, 7, 14, 28, and 70 days post right sciatic nerve transection 
(SNT) and resection, and naïve rats.  The tissue was frozen, sectioned at 12 - 14 μm with 
a Leica CM 1850 Leica (Microsystem Inc. Bannockbum, IL). Sections were thaw 
mounted to gelatin-coated SuperFrost slides (Fisher Scientific; Pittsburg, PA) and dried 
for 1 hr at 37C. Every fifth section was used to reduce the possibility of evaluating a 
neuron twice. Sections were washed three times for 10 min in phosphate buffered saline 
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(PBS) and incubated in 0.5% bovine serum albumin (BSA), and 0.5% 
polyvinylpyrolidone (PVP) in PBS with 0.3% Triton X-100 (PBS-T) with primary 
antiserum for 4 days. For VGLUT 2 detection, rabbit antiserum (Sigma) against VGLUT 
2 was used at 1:2000 dilution. The tissue was rinsed three times in PBS and incubated in 
AlexaFluor 488 goat anti-rabbit IgG secondary antibody in PBS-T (1:1500) for 1 hr at 
room temperature. Sections were rinsed two times in PBS following secondary antibody 
incubation and incubated in 4',6-diamidino-2-phenylindole (DAPI) for nucleus staining 
for 15 min. All sections were rinsed three more times in PBS and coverslipped with 
ProLong Gold mounting medium (Molecular Probes). 
2.5. Image analysis: 
Images were acquired using a 20X objective on an Olympus BX51 
epifluorescence microscope (Olympus; Center Valley, PA) equipped with a SPOT RT740 
quantitative camera (Diagnostic Instruments; Sterling Heights, MI). Three random fields 
of view were imaged for each DRG section. Images were saved as uncompressed TIFF 
files. The exposure time for all images was the same for all tissue sections from all 
animals. The exposure time was determined empirically so that weakly stained neurons 
could be distinguished for tracing, but that intensely stained neurons were not 
oversaturated [16,17]. This approach allowed images to be evaluated along the linear 
aspect of immunofluorescence intensity [17].   Captured images were 1600 X 1200 pixels 
with 2.69 pixels per micrometer. All neuron profiles with clearly visible nuclei that were 
not touching the edge of the image were traced with a Cintiq 21UX interactive pen 
display (Wacom; Kita Saitama-Gun, Saitama, Japan), using the freehand selection tool in 
Image J software (NIH). Nuclei were excluded from the regions of interest, making each 
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region of interest correspond to the cytoplasmic profile of a single DRG neuron [16, 17]. 
Images were acquired at a bit depth of 8, so pixel intensities ranged from 0 (darkest) to 
255 (lightest) on a grayscale. The mean gray value and area in µm2 for each cytoplasmic 
profile were measured and copied to a spreadsheet. The values for area (µm
2
) were 
binned into small (<400 µm
2
), medium (400–799.99 µm
2
), and large (≥800 µm
2
) sized 
categories to indicate three broadly defined neuronal subpopulations that corresponded to 
C, Aδ, and Aα/β fibers, respectively [18, 19].  
For sciatic nerve analysis, images were obtained using the same methods as were 
used for DRG. To calculate mean gray intensity, three boxes were drawn near the end of 
the nerve transection on the side proximal to the DRG. Each box covered an area equal to 
10,000 μm
2
 and a mean gray intensity (MGI) for each was obtained. An average MGI for 
the sciatic nerve was calculated for each rat. 
All data obtained were normalized to allow the evaluation of different time points 
in the same statistical test. The normalization was performed following this formula: 
X= (individual mean gray intensity per rat × 100) ÷ the mean of total naïve mean gray intensity 
Where X is equal to the percentage change of mean gray intensity per injured rat in 
relation to the naïve rats. 
2.6. Western Blot for total Vesicular glutamate transporter 2: 
For immunoblotting, rats (n = 6), ten weeks post sciatic nerve transection, control) 
were killed with CO2 and decapitated. Right L4 DRG was removed rapidly and 
homogenized [15]. DRG were homogenized individually with lysis buffer (50mM Tris 
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pH 7.4, 2 mM EDTA, 0.05% Triton-X 100) with phosphatase inhibitor cocktail I and II 
and protease inhibitor (Sigma). Homogenates were centrifuged (70,000 rpm, 20 minutes) 
and the supernatant were flash-frozen using liquid nitrogen for later use. All protein 
samples were kept at -80C. Protein concentration of the supernatant was measured (BCA 
Protein Assay Kit, Pierce, Rockford, Ill) to normalize the samples. Rabbit anti-VGLUT 2 
antibody (Sigma) was bound to M-280 Dynabeads (Invitrogen) conjugated with sheep 
anti-rabbit antibody [15]. Equal amounts of total protein (75mg/mL) were exposed to 
rabbit anti-VGLUT 2 antibody beads (overnight, 4C) for VGLUT 2 purification [15]. 
Samples were exposed to a magnet to collect the bead antibody-protein complex. The 
purified protein was eluted using Laemmli buffer (10mM Tris, 1 mM EDTA, 2.5% SDS, 
5% β-mercaptoethanol, 5% bromophenol blue, pH 8.0) and by heating the samples at 
100C for three min. VGLUT 2 electrophoresis was performed on a 12.5% homogenous 
polyacrylamide gel (Phast-System, Promega) [15] along with molecular weight standards 
(Novagen). Proteins were transferred to a nitrocellulose membrane in a buffer of 25mM 
Tris, pH 8.0, 192mM glycine and 20% methanol at 25mA for 20 minutes. 
Immunoblotting was performed using the Protoblot II AP System (Promega) [15]. 
Membranes were dried at 37C, rinsed in 20mM Tris-HCL, 150mM NaCl, and 0.05% 
Tween 20, pH 7.5 (TBST), washed in 1% bovine serum albumin (BSA) in TBST, and 
incubated in rabbit anti-VGLUT 2 antibody (1/1000, TBST) for 1 hour at room 
temperature. Membranes were washed in TBST followed by incubation in alkaline 
phosphatase conjugated goat anti-rabbit antibody for 30 minutes. Membranes were 
washed twice in TBST and TBS. Membranes were incubated in Western Blue stabilized 
substrate for alkaline phosphatase (Promega; 5-bromo-4-chloro-3-indolyl-phosphate, 
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nitro blue tetrazolium, the membranes then dried overnight in room temperature. Dried 
membranes were scanned and the obtained images were analyzed by tracing the bands 
using the freehand selection tool in Image J software (NIH) to obtain a mean gray 
intensity. 
2.7. Statistics:  
Data from the analyses are reported as mean value of the changes in mean gray 
intensity with standard deviation. A one-way ANOVA test, followed by Tukey testwas 
used to determine differences between nerve injury and control groups (Prism version 
5.01, GraphPad Software Inc., San Diego, CA). In all analyses, P values less than 0.05 
were considered significant.   
3. Results 
3.1. Vesicular glutamate transporter 2 IR in Dorsal Root Ganglia: 
At day 2 and 28, VGLUT2 immunoreactivity (IR) in L4 DRG neurons post SNT 
rats appeared to decrease compared to DRG neurons from naïve rats (Figure 3.1). 
Therefore, the VGLUT2 IR intensities of the total immunoreactive neurons and the three 
different sizes of DRG cell bodies were analyzed (Figure 3.2). On Day 2, total neuron 
VGLUT2 IR percentage intensity of L4 DRG cell bodies (Figure 3.2 A) from the SNT 
rats (68.14 ± 4.4/ µm
2
) was less (P < 0.05) than naïve rats (100 ± 7.79/ µm
2
). By day 7 
and 14 post injury, VGLUT2 IR returned to normal intensity levels. Day 28 post SNT, 
VGLUT2 IR of L4 DRG cell bodies showed another decrease in the percentage intensity 
similar to day 2 (68.01± 4.38/ µm
2
, day 28 post SNT vs. 100 ± 7.79/ µm
2
 control). For 
both day 2 and 28 post SNT, DRG neurons size subgroups also showed significant 
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decrease in VGLUT2 IR compared with naïve DRG neurons (Figure 3.2 B, C, and D). 
Day 70 post SNT, only small sized neurons subgroups (figure 3.2 B) continued to have a 
significant decrease (P < 0.05) in VGLUT2 IR intensity of L4 DRG cell bodies from 
naïve rats (100 ± 7.79/ µm
2




Figure 3.1: Vesicular glutamate transporter 2 (green) immunoreactivity (IR) and , DAPI 
(blue) nuclear staining in rat L4 dorsal root ganglia (DRG) following 1, 2, 7, 14, 28, and 
70 days post right sciatic nerve transection (SNT). DRG sections were processed with a 
rabbit VGLUT2 antiserum and photographed under identical conditions. In day 2 and 28 
sections, VGLUT2 IR was decreased in all neuronal cell sizes compared to control 
sections. No observable change in VGLUT2 IR in any of the neuronal cell sizes occurred 
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Figure 3.2: Image analysis of vesicular glutamate transporter 2 (VGLUT 2) 
immunoreactivity (IR) in L4 DRG neurons after 1, 2, 7, 14, 28, and 70 days post SNT. 
Data are presented as percentage change in mean gray intensity. DRG neurons were 
categorized into three area size groups: small (<400 µm
2
), medium (400–799.99 µm
2
), 
and large (≥800 µm
2
). Total VGLUT2 IR (A) decreased at 2 and 28 days post SNT 
compared to control rats. This overall decrease was similar in small (B), medium (C), and 
large (D) cell size subgroups. In addition, small sized neurons continued to show a 
decrease in VGLUT 2 IR 70 days post SNT compared to control. (* P < 0.05). One-way 
ANOVA followed by Tukey test were used.     
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3.2. Vesicular glutamate transporter 2 Western blot: 
Western blot of L4 DRG showed one characteristic band for VGLUT2 at a 
molecular weight of 65 kDa (Figure 3.3 (a)). Analysis of the rat L4 DRG showed no 
significant change between naïve and day 70 post SNT rats (Figure 3.3 (b)). 
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Figure 3.3: Western blot analysis of vesicular glutamate transporter 2 (VGLUT2) within 
the L4 DRG from 70 days post SNT (n=3) and controls (n=3) rats. (a) Western blot 
shows VGLUT2 immunoreaction (65 kDa) from L4 DRG of 70 days post SNT and 
controls rats. (b) Statistical analysis of VGLUT 2 immunoreactivity between post SNT 
and control rats. No significant change was found.  
3.3. Vesicular glutamate transporter 2 IR in Sciatic Nerve: 
At day 1, 2, and 28, VGLUT2 immunoreactivity (IR) in right sciatic nerve 
segments proximal to the area of transection (pre transaction) were increased compared to 
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intact right sciatic nerve from naïve rats (Figure 3.4). Therefore, the VGLUT2 IR 
intensities of the immunoreactive nerve fibers were analyzed (Figure 3.5). 
At day 1 post SNT, VGLUT2 IR percentage change in mean gray intensity 
(185.83 ± 24.66/ µm2) at the right sciatic nerve segment (pre transection) increased 
significantly (P < 0.05) compared to control rats (100 ± 15.28/ µm2). This increase 
persisted at day 2 post SNT, SNT rat 204.13 ± 34.99/ µm2 vs. Control rats 100 ± 15.28/ 
µm2(figure 3.5). VGLUT2 IR percentage change in mean gray intensity returned to 
normal levels at day 7 and 14 post SNT. However, at day 28 post SNT VGLUT2 IR 
percentage change in mean gray intensity (145.89 ± 20.21/ µm2) again showed a 
significant increase (P < 0.05) compared to control rats (100 ± 15.28/ µm2), only to 




Figure 3.4: Vesicular glutamate transporter 2 (green) IR in rat right sciatic nerve 
following 1, 2, 7, 14, 28, and 70 days post right SNT. Sciatic nerve sections were 
processed with a rabbit VGLUT2 antiserum and photographed under identical conditions. 
In day 1, 2, and 28 sections, VGLUT2 IR were relatively high compared to control 





























Figure 3.5: Image analysis of vesicular glutamate transporter2 (VGLUT2) 
immunoreactivity (IR) in right sciatic nerve after day 1, 2, 7, 14, 28, and 70 post sciatic 
nerve transection (SNT). Data are presented as percentage of mean gray intensity area 
from pre sciatic nerve transection site. VGLUT2 IR increased at 1 and 28 days post SNT 
compared to Control rats. (* P < 0.05). One-way ANOVA followed by Tukey test were 
used.    
 
4. Discussion 
In this study, we evaluated vesicular glutamate transporter 2 immunoreactivity in 
DRG neuronal bodies and in the sciatic nerve proximal to the site of transection and 
resection in six different time points. Peripheral nerve injury can produce a chronic 
painful state of neuropathy [23]. This painful state leads to multiple changes in DRG 
neuronal cell bodies and axons. In chronic pain conditions, DRG neurons constantly 
modify their neurotransmitter production and concentration [15]. DRG neurons primarily 
use glutamate as their excitatory neurotransmitter [9] and VGLUT2 is an essential protein 
for normal pain expression [25].  Furthermore, DRG neurons with transected axons 
establish a regenerative process to reinnervate their target tissue. During the regenerative 
phase, glutamate can be used as an exocytosed chemical mediator for determining 
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directionality in axonal growth cones [26, 29].  Alterations in VGLUT2 levels observed 
in the current study, therefore, could be influenced by one or both processes.   
Sciatic nerve crush is a common model used in peripheral nerve axonotmesis. 
Complete motor and sensory recovery is expected to be complete by ten to twelve weeks 
post injury [27]. The validity of nerve crush model in producing replicable nerve injury is 
still debatable. This is evident by different morphological and functional results obtained 
at similar time points by different researchers [27, 28]. To avoid any uncertainty in our 
results, we used a complete sciatic nerve transection and reapposition model. Because the 
severed nerve was resected this provides a conduit for regeneration. Furthermore, we 
studied the regenerated nerve at six different time points to observe VGLUT2 changes in 
acute (day 1 &2), sub-acute (day 7 & 14), and chronic (day 28 & 70) phases.  
In the acute phase, VGLUT2 IR levels decreased remarkably in DRG neuronal 
cell bodies at day 2. This decrease is associated with a significant increase in VGLUT2 
IR level in the sciatic nerve at the site of transection. In contrast, VGLUT2 IR levels in 
both the DRG and sciatic nerve return to normal levels in the sub-acute phase. The 
chronic phase, however, exhibited a similar pattern as the acute phase. There is a lack of 
similar research in rat models, but a number of explanations can be drawn from our 
results. First, similar to what happens in the case of acute phase of peripheral 
inflammation [15] DRG neurons increase the trafficking of VGLUT2 synaptic vesicles 
into the axons.  This is an inflammatory response due to the injury.  In addition, there is 
an increased amount of VGLUT2 IR at the transection site due to an accumulation of 
synaptic vesicles. In the sub-acute phase, as the inflammation subsides, VGLUT2 IR 
returns to normal levels. In this phase, axonal regeneration is occurring, but it appears to 
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have no significant effect on the amount of the VGLUT 2. In beginning of the chronic 
phase, where the axonal regeneration process peaks, there is a decrease in DRG VGLUT2 
IR and an increase in sciatic nerve VGLUT2 IR. This may indicate an increase in 
production of VLGUT2 in the neuronal cell body with a concurrent elevation of 
trafficking of VGLUT2 synaptic vesicles. Eventually, as DRG neurons have completed 
the regenerative process, the DRG neuronal cell bodies adjust their VGLUT2 production 
to accommodate the newly regenerated axonal needs for vesicular glutamate. 
Further studies are needed to establish VGLUT2 activity changes in DRG, sciatic 
nerve, and spinal cord following longer time period or until full recovery is achieved. In 
addition, functional assessment studies are needed to determine if VGLUT2 






VESICULAR GLUTAMATE TRANSPORTER 1 AND GLUTAMINASE 
EXPRESSION IN RAT DORSAL ROOT GANGLION NEURONS DURING THE 
REGENERATIVE PHASE FOLLOWING SCIATIC NERVE TRANSECTION 
1. Introduction 
In previous chapters we discussed the changes in vesicular glutamate transporter 2 
(VGLUT2) in dorsal root ganglia (DRG) and sciatic nerve after sciatic nerve crush (SNC) 
or transection and resection. We conclude that, after SNC, VGLUT2 IR in DRG neuronal 
cell bodies increases at day 7. In the sciatic nerve transection and resection (SNT) model, 
VGLUT2 IR decreases at day 2 and 28 post injury in the DRG neuronal cell bodies. 
These studies are consistent with the changes in glutamate metabolism cycle. 
In addition to VGLUT2, vesicular glutamate transporter 1 (VGLUT1) and 
glutaminase (GLS) are markers for glutamate metabolism. GLS is the primary enzyme in 
the glutamine cycle for the conversion of glutamate from glutamine. Glutamate is 
transported into vesicles by the vesicular glutamate transporters 1 and 2 [24]. VGLUT1 in 
DRG neuronal cell bodies is mainly localized in medium to large neurons whereas 
VGLUT2 is localized in small to medium neurons [12]. Because glutamate is the most 
abundant excitatory neurotransmitter in the adult central nervous system (CNS) [10]  
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and has critical roles in CNS function, it is crucial to understand its role in different 
injury models in order to have a clearer understanding of regeneration and neuropathic 
pain.  
Previous studies indicate that glutamate metabolism is altered in DRG neurons 
after axonal injury. Following SNT in rats, glutamate levels double in the nerve at 15 
days post-injury [13]. After dorsal root crush in cats, glutamate levels in the DRG 
decrease from 2-4 days, but regain normal levels from 10-25 days [14]. Glutamate levels 
are diminished 4-25 days in dorsal roots following dorsal root crush [14]. Sciatic nerve 
transection in mice at 7 days decreases the overall number of DRG neurons for vesicular 
glutamate transporters 1 & 2 [12]. Despite an overall decrease, VGLUT 2 increases in a 
subpopulation of small diameter neurons after 7 days of sciatic nerve transaction [12]. 
The effect of peripheral nerve injury or regeneration on DRG glutamate metabolism, 
however, has not been studied systematically. 
In the present study, I evaluated vesicular glutamate transporter 1 and glutaminase 
as additional markers of glutamatergic function in DRG cell bodies during the 
regenerative phase following sciatic nerve transection and resection in the rat. VGLUT1 
and GLS were evaluated in DRG with immunohistochemistry at day 1, 2, 7, 14, 28, and 
70 after transection and resection of the sciatic nerve (SNT).   
2. Materials and Methods 
2.1. Animals: 
Adult Sprague Dawley rats (n=27; 250-350 g) were housed in a 12-hr-light: 12-
hr-dark cycle and given free access to food and water. Procedures were approved by the 
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Oklahoma State University Center for Health Sciences Institutional Animal Care and Use 
Committee. All appropriate efforts were made to minimize the number of animals used in 
this study. Rats were randomly assigned to specific experiments, irrespective of their 
gender. Gender differences were not investigated in this study. 
2.2. Surgery:  
All surgeries were performed on animal anesthetized by 2%-3% isoflurane 
inhalation. Under deep anesthesia, the rat right sciatic nerve was exposed at mid-thigh 
level and cut with a sharp blade. The nerve was reapposed and sutured using ETHILON 
8-0 black monofilament Nylon for alignment. Muscles and skin were sutured in layers. 
The animals were allowed to recover from the anesthesia in a warmed cage and then were 
housed individually until the day of perfusion.  Naïve rats were used as control.  
2.3. Tissue Preparation: 
Rats were anesthetized with tribromoethanol [Avertin;2.5% (w/v)] and xylazine 
and perfused through the ascending aorta with 75 ml of calcium-free Tyrode’s solution 
(pH 7.3), followed by 300 ml of fixative 0.2% paraformaldehyde (w/v), 0.8% (w/v) picric 
acid in 0.1M phosphate buffer, pH 7.3 [16]. Right L4 DRG were removed and placed for 
4 hrs. in the same fixative used for perfusion at 4C. DRGs were transferred to 20% 
sucrose in 0.1M phosphate buffer, pH 7.3 for 24–48 hrs. at 4C.  
2.4. Immunofluorescence:  
Immunohistochemical localization of GLS and VGLUT 1 was performed for six 
different experimental time points: 1, 2, 7, 14, 28, and 70 days post right sciatic nerve 
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transection (SNT) and resection, and naïve rats.  The tissue was frozen, sectioned at 12 - 
14 μm with a Leica CM 1850 Leica (Microsystem Inc. Bannockbum, IL). Sections were 
thaw mounted to gelatin-coated SuperFrost slides (Fisher Scientific; Pittsburg, PA) and 
dried for 1 hr at 37C. Every fifth section was used to reduce the possibility of evaluating 
a neuron twice. Sections were washed three times for 10 min in phosphate buffered saline 
(PBS) and incubated in 0.5% bovine serum albumin (BSA), and 0.5% 
polyvinylpyrolidone (PVP) in PBS with 0.3% Triton X-100 (PBS-T) and primary 
antiserum for 4 days. For GLS detection, polyclonal rabbit antiserum against whole GLS 
(gift from Dr. N. Curthoys, Colorado State University, Fort Collins, Colo) was used at 
1:20,000 dilution. For VGLUT 1 detection, rabbit antiserum (Sigma) against VGLUT 1 
was used at 1:2000 dilution. The tissue was rinsed three times in PBS and incubated in 
AlexaFluor 488 goat anti-rabbit IgG secondary antibody in PBS-T (1:1500) for 1 hr at 
room temperature. Sections were rinsed two times in PBS following secondary antibody 
incubation, and then incubated in DAPI for nucleus staining for 15 Min. All sections 
were rinsed three more times in PBS and coverslipped with ProLong Gold mounting 
medium (Molecular Probes). 
2.5. Image analysis: 
Images were acquired using a 20X objective on an Olympus BX51 
epifluorescence microscope (Olympus; Center Valley, PA) equipped with a SPOT RT740 
quantitative camera (Diagnostic Instruments; Sterling Heights, MI). Three random fields 
of view were imaged for each DRG section. Images were saved as uncompressed TIFF 
files. The exposure time for all images was the same for all tissue sections from all 
animals. The exposure time was determined empirically so that weakly stained neurons 
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could be distinguished for tracing, but that intensely stained neurons were not 
oversaturated [16,17]. This approach allowed images to be evaluated along the linear 
aspect of immunofluorescence intensity [17].   Captured images were 1600 X 1200 pixels 
with 2.69 pixels per micrometer. All neuron profiles with clearly visible nuclei that were 
not touching the edge of the image were traced with a Cintiq 21UX interactive pen 
display (Wacom; Kita Saitama-Gun, Saitama, Japan), using the freehand selection tool in 
Image J software (NIH). Nuclei were excluded from the regions of interest, making each 
region of interest correspond to the cytoplasmic profile of a single DRG neuron [16, 17]. 
Images were acquired at a bit depth of 8 and pixel intensities ranged from 0 (darkest) to 
255 (lightest) on a grayscale. The mean gray value and area in µm
2
 for each cytoplasmic 
profile were measured and copied to a spreadsheet. The values for area (µm
2
) were 
binned into small (<400 µm
2
), medium (400–799.99 µm
2
), and large (≥800 µm
2
) sized 
categories to indicate three broadly defined neuronal subpopulations that corresponded to 
C, Aδ, and Aα/β fibers, respectively [18, 19].  
All data obtained were normalized to allow the evaluation of different time points 
in the same statistical test. The normalization was performed following this formula: 
X= (individual mean gray intensity per rat × 100) ÷ the mean of total naïve mean gray intensity 
Where X is equal to the percentage change of mean gray intensity per injured rat in 
relation to the naïve rats. 
2.6. Statistic:  
Data from the analyses are reported as mean value with standard error of the 
mean. A one-way ANOVA test, followed by Tukey post-test was used to determine 
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differences between nerve injury and control groups (Prism version 5.01, GraphPad 
Software Inc., San Diego, CA). In all analysis, P values less than 0.05 were considered 
significant.   
3. Results 
3.1. Glutaminase IR in Dorsal Root Ganglia: 
At day 14, GLS immunoreactivity (IR) in L4 DRG neurons post SNT rats 
qualitatively were increased compared to DRG neurons from naïve rats (Figure 4.1). 
Therefore, the GLS IR intensities of the total immunoreactive neurons and three different 
sizes of DRG cell bodies were analyzed (Figure 4.2). At Day 14, the total, medium and 
large sized neurons have an increase in GLS IR in L4 DRG cell bodies (Figure 4.2 A, C, 
and D) from the SNT rats (140.38 ± 40.01/ µm
2
) compared to naïve rats (100 ± 6.76/ 
µm
2
; (P < 0.05). This increase in GLS intensity was not seen in day 1, 2, 7, 28, and 70 
post SNT. In addition, day 14 post SNT DRG neurons small sized neurons subgroup did 




Figure 4.1: Glutaminase (green) immunoreactivity (IR) and DAPI (blue) nuclear staining 
in rat L4 dorsal root ganglia (DRG) following 1, 2, 7, 14, 28, and 70 days post right 
sciatic nerve transection (SNT). DRG sections were processed with a rabbit VGLUT2 
antiserum and photographed under identical conditions. At day 14, GLS IR was more 
intense in neurons compared to control sections. No noticeable change in GLS IR 
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Figure 4.2: Image analysis of Glutaminase (GLS) immunoreactivity (IR) in L4 DRG 
neurons after 1, 2, 7, 14, 28, and 70 days post sciatic nerve transection (SNT). Data are 
presented as percentage change in mean gray intensity. DRG neurons were categorized 
into three area size groups: small (<400 µm
2
), medium (400–799.99 µm
2
), and large 
(≥800 µm
2
). Small sized neurons GLS IR (B) increased at day 70 post SNT compared to 
control rats. (* P < 0.05). One-way ANOVA followed by Tukey test were used. 
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3.2. Vesicular glutamate transporter 1 IR in Dorsal Root Ganglia: 
At day 2, VGLUT1 immunoreactivity (IR) in L4 DRG neurons post sciatic nerve 
transection rats qualitatively decreased compared to DRG neurons from naïve rats 
(Figure 4.3). Therefore, the VGLUT1 IR intensities of the total immunoreactive neurons 
number and three different sizes of DRG cell bodies were analyzed (Figure 4.4). Day 2, 
total neuronal VGLUT1 IR intensity of L4 DRG cell bodies (Figure 4.4 A) from the SNT 
rats (74.17± 4.22/ µm
2
) was less (p < 0.05) than naïve rats (100± 8.23/ µm
2
). At day 7, 
14, 28 and 70 post injury, VGLUT1 IR returned to normal intensity levels. In addition, 
neurons size subgroups from day 2 post SNT DRG showed a significant decrease in 
VGLUT1 IR compared with naïve DRG neurons except for medium sized DRG neurons 




Figure 4.3: Vesicular glutamate transporter 1 (green) immunoreactivity (IR) and DAPI 
(blue) nuclear staining in rat L4 dorsal root ganglia (DRG) following 1, 2, 7, 14, 28, and 
70 days post right sciatic nerve transection (SNT). DRG sections were processed with a 
rabbit VGLUT1 antiserum and photographed under identical conditions. In day 2 
sections, VGLUT1 IR was diminished compared to control sections. No noticeable 
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Figure 4.4: Image analysis of vesicular glutamate transporter 1 (VGLUT1) 
immunoreactivity (IR) in L4 DRG neurons after 1, 2, 7, 14, 28, and 70 days post sciatic 
nerve transection (SNT). Data are presented as percentage change in mean gray intensity.  





), and large (≥800 µm
2
). Total VGLUT1 IR (A) decreased at day 2 post 
SNT compared to control rats. This overall decrease was similar in small (B), and large 





In pathological conditions, DRG neurons constantly modify their neurotransmitter 
concentration and production [15]. DRG neurons primarily use glutamate as their 
excitatory neurotransmitter [9]. In addition to VGLUT2, glutaminase and vesicular 
glutamate transporter 1 are markers of the glutamate cycle [11]. In this study, I evaluated 
glutaminase and vesicular glutamate transporter 1 immunoreactivity at DRG neuronal 
bodies after sciatic nerve transection and resection at six different time points.   
The sciatic nerve transection and resection model was used allowing for analysis 
of changes of VGLUT1 and GLS under the same conditions as my previous studies. In 
addition, the same six time points of the regenerative process was analyzed for changes in 
the GLS and VGLUT1 IR in the acute (day 1 &2), sub-acute (day 7 & 14), and chronic 
(day 28 & 70) phases. This allowed for comparisons between changes in GLS and 
VLGLUT 1 with changes observed for VGLUT 2.  
Similar to changes observed for VGLUT 2, VGLUT 1 IR decreases in DRG 
neurons at day 2 then returns to normal levels. This decrease in VGLUT1 IR may be due 
to an inflammation response or an early regenerative response. This decrease in VGLUT1 
immunoreactivity may indicate increased trafficking of synaptic vesicles for elevated 
glutamatergic neurotransmission in the spinal cord.  Alternatively, vesicular release of 
glutamate may be occurring at the regenerating peripheral process. 
Furthermore, GLS exhibits the same general pattern of change in IR observed in 
VGLUT 1 & 2. Although the level of GLS IR was unchanged significantly at day 2, GLS 
IR was significantly increased at day 14 post SNT in DRG neurons. This indicate that 
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glutamate cycle follow the same pattern in glutamate synthesis as in glutamate 
packaging.   There are no previous studies on GLS after sciatic nerve transection. 
However, in inflammation models, GLS increases 7 days post injury [15]. Thus, we can 
assume that GLS IR does not follow the same path in inflammation during nerve injury 
as in peripheral inflammation.   
Further studies are needed to establish GLS and VGLUT1 activity changes in 
DRG, sciatic nerve, and spinal cord following longer time periods or until full recovery is 
achieved. In addition, functional assessment studies are needed to determine if GLS and 






SUMMARY AND FUTURE WORK 
Neuropathic pain is a common complication of peripheral nerve injuries. This is 
due to the prolonged time of recovery and misguided directional axonal growth. In pain 
studies, it has been revealed that glutamate neurotransmission has a critical role in the 
noxious stimulus sensation. The glutamate cycle has several well established markers: 
vesicular glutamate transporters 1 & 2 and glutaminase. However, systemic studies for 
changes in vesicular glutamate transporters 1 & 2 and glutaminase after peripheral nerve 
injuries have not been done. Thus, in this thesis project I studied the changes in vesicular 
glutamate transporters 1 & 2 and glutaminase systemically at time points that represent 
the acute (day 1 & 2), subacute (day 7 & 14), and chronic (day 28 & 70) phases in 
peripheral nerve regeneration. The peripheral nerve injury models were used imitate two 
types of peripheral nerve injury in human. The first model, the sciatic nerve crush (SNC), 
represents the axonotmesis injury type. The second model, the sciatic nerve transection 
(SNT), represents the neurotemsis injury type. Additionally to avoid the formation of 
neuroma in the transection model, the severed sciatic nerve was sutured together to 
bridge the gap between the two ends of the transected nerve. This provides the best 
environment for the nerve to grow to its original target.
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In summary, my results showed an interesting alteration for vesicular glutamate 
transporters 1 & 2 and glutaminase immunoreactivity that differ in each model. For the 
SNC model, I examined VGLUT 2 at the subacute phase in conjunction with Gap43. 
VGLUT 2 at day 7 post injury showed significant increases compared to sham operated 
rats. No significant change was seen at day 14. Gap43 immunoreactivity levels examined 
to confirm that our model produced a nerve injury. Gap43 immunoreactivity level is 
increased in the regenerative process following nerve injury. Consistent with the SNC 
model, Gap43 levels were elevated at day 7 and 14 post injury. 
 In the sciatic nerve transection and resection model, examination of VGLUT 2 
immunoreactivity in the DRG neurons showed a decrease at day 2 and 28 post injury in 
all cell sizes. This decrease occurs only in small sized neurons at day 70 post injury. 
VGLUT 2 immunoreactivity was increased at the proximal end of the transected sciatic 
nerve at day 1, 2, and 28 post injury. On the other hand, studies of VGLUT 1 
immunoreactivity at the DRG neurons showed a decrease in neuronal cell bodies only at 
day 2 post sciatic nerve transection injury. Furthermore, studies of glutaminase 
immunoreactivity of the DRG neurons revealed an increase at day 14 post SNT injury in 
the neuronal cell bodies. 
 In conclusion, these immunohistochemistry studies for VGLUT 1 & 2 and 
glutaminase provide insight into part of the story of neuronal response to injury. To more 
fully understand the underlying mechanisms of changes in the glutamate metabolism 
cycle after peripheral injury, further studies need to be done. For example, western blot 
studies of VGLUT 1 & 2 and GLS for the acute, subacute, and chronic phases need to be 
done in conjunction with in situ hybridization studies to compare VGLUT 1 & 2 and 
46 
 
GLS proteins amount with their mRNA levels. Furthermore, behavioral studies are 
needed to see if the molecular change observed in glutamate cycle is comparable with the 
alteration in pain sensation following peripheral nerve injury. Lastly, an understanding of 
the molecular and physiological changes after peripheral nerve injuries is a necessary step 
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